It's a bit of mystery why there's so much discrepancy in drug approval processes among the different provinces. There was hope that the central review would be a positive thing to speed things up, but actually it turned out to be the opposite.
There will also be an ethical dimension to the whole process of diagnosing Alzheimer's before dementia. What do you tell people when they're 50? Do you tell them they have Alzheimer's, that although they don't have symptoms yet, we can see it on their scan or their lumbar puncture? Do we tell them they have mild symptoms of Alzheimer's and they'll have dementia in five years?
There's perhaps an ethical dimension and a resource-use aspect. You will be using more technology, more scans, more lumbar punctures, more specialized units. There may be a social debate that would be at the national level on the ethics of earlier diagnosis if there's no effective prevention. That's one aspect of the answer.
As far as harmonizing diagnoses and management is concerned, we will continue to do that, but this is not driven by governments. This is driven by the base, which is nice. It's doctors and lay public societies, and that will continue.